Lead article on FDA regulation of ophthalmic drugs
Dr. Novack published the lead article in the June 2024 issue of the American Journal of Ophthalmology. In this article, he showed a time line of key U.S. FDA registration and the availability of ocular hypotensive drugs (i.e., drugs that decrease elevated intraocular pressure) to patients and their doctors. He concludes that “Concomitant with public […]
Dr. Novack’s contributions to the Journal of Ocular Pharmacology and Therapeutics highlighted
In a recent article in the Journal of Ocular Pharmacology and Therapeutics (JOPT), the present editor, Uday Kompella PhD of the University of Colorado, joined with past editors Craig Crosson Ph.D., David E. Potter, Ph.D., and W. Dan Stamer, Ph.D. to mark the 40th anniversary of the journal. In the article, they note the Dr. […]
Dr. Novack selected to be fellow of AOPT
Dr. Novack was selected to be a fellow of the Association for Ocular Pharmacology and Therapeutics. The Association for Ocular Pharmacology and Therapeutics is a global organization for scientists and individuals from all disciplines related to ocular pharmacology and its therapeutic applications. Fellows of AOPT are nominated by their peers based upon service to the […]
Compounding of Low-Concentration Atropine for Myopia Control
I call attention to this paper of mine just published in Eye & Contact Lens together with colleagues Drs. Kathryn Richdale, Erin Tomiyama and Mark Bullimore – a survey of the variability of atropine formulation, sterility and stability testing and storage requirements for compounded low dose atropine for myopia prevention. https://pubmed.ncbi.nlm.nih.gov/36083169/
Dr. Novack honored by American Academy of Ophthalmology
Gary D. Novack, Ph..D. was honored by the American Academy of Ophthalmology (AAO). In the AAO’s honors for its 2022 Annual Meeting, Dr. Novack was cited by its Secretariat for his work on the Academy’s journal, Ophthalmology Glaucoma. Dr. Novack serves as both an author and reviewer for this journal.
Value of medical writers discussed in top journal
In a recent article in JAMA Oncology on the use of surrogate endpoints in oncology, del Paggio et al identified industry funding for nearly all. They further highlighted the use of medical writers in papers published on this work to be of concern…
Client publishes 100th paper – PharmaLogic wrote the first one
Glaukos announced that 200 papers published on their glaucoma product, the iStent. . We’re pleased to say that Dr. Novack was the medical writer for lead authors Dr. Thomas Samuelson and L. Jay Katz on the first one, in Ophthalmology…
Off-label use: Article in the American Journal of Ophthalmology
Together with UC Davis Ophthalmology faculty member, Ala Moshiri, M.D., Ph.D., I published a commentary in the American Journal of Ophthalmology regarding the challenges to making off-label use of products a standard of care in retina therapies in ophthalmology…